Schizophrenia trials in Poland

In Poland 13 Also abroad 473

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Where
Gdansk, Katowice, Lublin, Poznan, Szczecin, Warsaw, Wroclaw, Zabrze
Age
5 years to 17 years
People
400 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT07424404 · EU 2025-524062-16-00
Phase 3Taking people
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
Where
Bialystok, Gdansk, Lodz, Zabrze
Age
18 years and over
People
135 worldwide
Run by
Newron Pharmaceuticals S.p.A.
See details and how to join2024-519836-18-00 · EU 2024-519836-18-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Where
Bydgoszcz, Katowice, Ścinawa
Age
55 years and over
People
370 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833
Phase 3Taking people
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Where
Bialystok, Poznan, Warsaw
Age
18 years to 65 years
People
472 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT07686263 · EU 2025-523664-20-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Gdansk, Ilawa, Lodz, Lublin, Poznan, Sochaczew
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Gdansk, Krakow, Lublin, Plewiska, Poznan, Warszawa
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2Taking people
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
Where
Gdansk, Lublin, Olkusz, Poznan, Zabrze
Age
18 years to 64 years
People
239 worldwide
Run by
Oryzon Genomics S.A.
See details and how to join2023-507372-42-00 · EU 2023-507372-42-00
No phaseNot yet taking people in Poland
Basal Stimulation Therapy in Adults With Schizophrenia Requiring Institutional Care
Where
Katowice, Rybnik
Age
55 years and over
People
12
Run by
The Jerzy Kukuczka Academy of Physical Education in Katowice
See details and how to joinNCT07769749
Phase 2Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Gdansk, Krakow, Plewiska, Poznan, Warsaw
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00
No phaseNot yet taking people in Poland
Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia
Where
Katowice, Rybnik
Age
18 years and over
People
140
Run by
The Jerzy Kukuczka Academy of Physical Education in Katowice
See details and how to joinNCT07748078
Phase 2Taking people
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Where
Bialystok, Gdansk, Lodz, Poznan
Age
18 years to 55 years
People
120 worldwide
Run by
Neurocrine Biosciences
See details and how to joinNCT07288333 · EU 2025-521868-35-00
No phaseEnrolling by invitation
Effects of Transcranial Direct Current Stimulation on Cognitive Rehabilitation in Schizophrenia
Where
Lodz
Age
18 years to 65 years
People
120
Run by
Medical University of Lodz
See details and how to joinNCT07273175
Phase 2/3Taking people
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Where
Gdansk, Gdańsk, Lublin, Wroclaw
Age
18 years to 55 years
People
287 worldwide
Run by
SyneuRx International (Taiwan) Corp
See details and how to joinNCT03094429 · EU 2024-519237-34-00